Comparative Analysis of the Effect of Native and Polymeric β-Cyclodextrins on the Solubility and Membrane Permeability of Baricitinib

E. S. Delyagina; Делягина Е. С.; A. A. Garibyan; Гарибян А. А.; I. V. Terekhova; Терехова И. В.

doi:10.31857/S0044453723080046

Comparative Analysis of the Effect of Native and Polymeric β-Cyclodextrins on the Solubility and Membrane Permeability of Baricitinib

Authors: Delyagina E.S.¹^,2, Garibyan A.A.¹, Terekhova I.V.¹
Affiliations:
1. Institute of the Chemistry of Solutions, Krestov Academy of Sciences
2. Ivanovo State University
Issue: Vol 97, No 8 (2023)
Pages: 1218-1224
Section: БИОФИЗИЧЕСКАЯ ХИМИЯ И ФИЗИКО-ХИМИЧЕСКАЯ БИОЛОГИЯ
Submitted: 27.02.2025
Published: 01.08.2023
URL: https://medjrf.com/0044-4537/article/view/668690
DOI: https://doi.org/10.31857/S0044453723080046
EDN: https://elibrary.ru/QTSHUE
ID: 668690

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

A study is performed of the effect native and polymeric β-cyclodextrins have on the solubility and membrane permeability of baricitinib, a new generation immunomodulator. It is found that native and polymeric β-cyclodextrins exhibit the same solubilizing effect in relation to baricitinib, while their effect on the membrane permeability of the drug differs. The increased solubility of baricitinib is due to the formation of inclusion complexes that have the same stability but are enthalpy-entropy stabilized in native β-cyclodextrin and enthalpy stabilized in polymeric β-cyclodextrin. The effect cyclodextrins on baricitinib’s coefficients of permeability of through a model membrane is discussed in terms of complexation, changes in the viscosity of the medium, and the state of the water boundary layer near the membrane’s surface.

Keywords

solubility, immunomodulator, baricitinib, native and polymeric β-cyclodextrins

References

Aletaha D., Neogi T., Silman A.J. et al. // Arthritis Rheumatol. 2010. V. 62. P. 2569. https://doi.org/10.1002/art.27584
Drug Approval Package: Olumiant (baricitinib). 2018. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/207924Orig1s000TOC.cfm
Olumiant product information, European public assessment report. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant#authorisation-details-section.
Garibyan A.A., Delyagina E.S., Agafonov M.A. et al. // J. Mol. Lig. 2022. V. 360. P. 119548. https://doi.org/10.1016/j.molliq.2022.119548
Alshetaili A.S. // Z. Phys. Chem. 2018. V. 233. https://doi.org/10.1515/zpch-2018-1323
FDA Briefing, Arthritis Advisory Committee Meeting document, AAC Brief NDA 207924 (2018).
Ansari M.J., Alschahrani S.M. // Saudi Pharm. J. 2019. V. 27. P. 491. https://doi.org/10.1016/j.jsps.2019.01.012
Zheng X.-Q., Huang J.-F., Lin J.-L. et al. // Colloids Surf. B. 2021. V. 199. P. 111532. https://doi.org/10.1016/j.colsurfb.2020.111532
Braga S.S. // Biomolecules. 2019. V. 9. P. 801. https://doi.org/10.3390/biom9120801
Allahyari S., Trotta F., Valizadeh H. et al. // Expert Opin. Drug Deliv. 2019. V. 16. P. 467. https://doi.org/10.1080/17425247.2019.1591365
Mura P. // Int. J. Pharm. 2020. V. 579. P. 119181. https://doi.org/10.1016/j.ijpharm.2020.119181
Renard E., Deratani A., Volet G. et al. // Eur. Polum. J. 1997. V. 33. P. 49. https://doi.org/10.1016/S0014-3057(96)00123-1
Di Cagno M., Nielsen T.T., Larsen K.L. et al. // Int. J. Pharm. 2014. V. 468. P. 258. https://doi.org/10.1016/j.ijpharm.2014.04.029
Vartak R., Patki M., Menon S. et al. // Ibid. 2020. V. 589. P. 119863. https://doi.org/10.1016/j.ijpharm.2020.119863
Zhang W., Gong X., Cai Y. et al. // Carbohydr. Polum. 2013. V. 95. P. 366. https://doi.org/10.1016/j.carbpol.2013.03.020
Дружининская О.В., Смехова И.Е. // Разработка и регистрация лекарственных средств. 2017. Т. 20. № 3. С. 144.
Amrhein J., Drynda S., Schlatt L. et al. // Int. J. Mol. Sci. 2020. V. 21. P. 6632. https://doi.org/10.3390/ijms21186632
Higuchi T., Connors K. // Adv. Anal. Chem. Instrum. 1965. V. 4. P. 117.
Dahan A., Miller J.M., Hoffman A. et al. // J. Pharm. Sci. 2010. V. 99. P. 2739–2749. https://doi.org/10.1002/jps.22033